Background. End-stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality secondary to cardiac and vascular causes, particularly sudden cardiac death (SCD). Left ventricular (LV) hypertrophy is a frequent finding and constitutes an independent predictor of mortality risk in these patients. Mineralocorticoid receptor antagonists (MRAs) are cardioprotective in heart failure patients and effectively reduce LV mass, but are considered inappropriate in patients with severe renal impairment, given their potential to cause hyperkalaemia. Recent data from small clinical studies suggest that MRAs may be safe in patients undergoing regular haemodialysis, but cardiovascular (CV) protection in these patients is unclear. We here review the literature on CV effects of MRA in dialysis patients and report the design of the Mineralocorticoid Receptor antagonists in End-stage renal Disease (MiREnDa) trial. Methods. The MiREnDa trial is a prospective randomized, placebo-controlled, double-blind, parallel group, multi-centre, intervention study investigating the effects of spironolactone (50 mg daily) compared with placebo in maintenance haemodialysis patients. The change in LV mass index (LVMI) as assessed by cardiac magnet resonance imaging (CMR) constitutes the primary efficacy end point. Secondary end points include changes in LV geometry and function, office and 24-h ambulatory blood pressure, cardiac arrhythmias, vascular function parameters, measures of heart failure and quality of life. Pre-dialysis potassium levels and the incidence of threatening hyperkalaemia ( pre-dialysis potassium ≥6.5 mmol/L) constitute safety end points.
A B S T R AC T
Background. End-stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality secondary to cardiac and vascular causes, particularly sudden cardiac death (SCD). Left ventricular (LV) hypertrophy is a frequent finding and constitutes an independent predictor of mortality risk in these patients. Mineralocorticoid receptor antagonists (MRAs) are cardioprotective in heart failure patients and effectively reduce LV mass, but are considered inappropriate in patients with severe renal impairment, given their potential to cause hyperkalaemia. Recent data from small clinical studies suggest that MRAs may be safe in patients undergoing regular haemodialysis, but cardiovascular (CV) protection in these patients is unclear. We here review the literature on CV effects of MRA in dialysis patients and report the design of the Mineralocorticoid Receptor antagonists in End-stage renal Disease (MiREnDa) trial. Methods. The MiREnDa trial is a prospective randomized, placebo-controlled, double-blind, parallel group, multi-centre, intervention study investigating the effects of spironolactone (50 mg daily) compared with placebo in maintenance haemodialysis patients. The change in LV mass index (LVMI) as assessed by cardiac magnet resonance imaging (CMR) constitutes the primary efficacy end point. Secondary end points include changes in LV geometry and function, office and 24-h ambulatory blood pressure, cardiac arrhythmias, vascular function parameters, measures of heart failure and quality of life. Pre-dialysis potassium levels and the incidence of threatening hyperkalaemia ( pre-dialysis potassium ≥6.5 mmol/L) constitute safety end points.
Conclusions. MiREnDa will investigate CV efficacy and safety of spironolactone in haemodialysis patients [clinical trials.gov NCT01691053].
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I N T RO D U C T I O N
End-stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality risk >20% in the USA and other parts of the world (2010 USRDS Annual data report). Cardiovascular (CV) mortality accounts for almost half of all-cause mortality [1] . Despite this excessively high CV risk, there is a paucity of efficacious medical interventions that improve outcomes in dialysis patients [2] [3] [4] . Left ventricular (LV) mass is considered to be an integral measure of the long-term effects of several CV risk factors, including hypertension, anaemia and chronic volume expansion, which are commonly found in ESRD patients [5] . Increased LV mass is found in up to 75% of subjects at the start of renal replacement therapy [6] . Moreover, LV mass is an independent predictor of survival and CV events [7] , particularly of sudden cardiac death (SCD) [8] . Consequently, a reduction in LV mass has been shown to have a favourable effect on the outcome independent of blood pressure [9] .
The adrenal mineralocorticoid aldosterone has been implicated in the pathogenesis of LV hypertrophy. This relationship is highlighted in patients with primary hyperaldosteronism (PHA), a state of excess aldosterone. These patients develop inappropriate or accelerated LV hypertrophy [10, 11] suggestive of a direct, blood pressure independent effect of aldosterone on the myocardium. Clinical trials investigating the efficacy of mineralocorticoid receptor antagonists (MRAs) support this hypothesis: MRA alone or in combination with angiotensin-converting enzyme inhibitors (ACEis) / angiotensin receptor blockers (ARBs) reduced LV mass in patients with essential hypertension [12] , treatment-resistant hypertension [13] or hypertension secondary to PHA [14] . A similar effect has been noted in patients with mild-to-moderate chronic kidney disease (CKD) with normal blood pressure. Even though the majority of these patients had a normal LV mass at baseline, 9 months of treatment with 25 mg spironolactone induced a significant LV mass reduction compared with placebo [15] .
Plasma levels of aldosterone have emerged as an indicator of adverse prognosis in several cardiac and non-cardiac conditions, including heart failure [16, 17] and acute myocardial infarction [18, 19] . We recently showed that high aldosterone levels are associated with an increased risk of all-cause death as well as SCD in diabetic dialysis patients [20] . Furthermore, pharmacological blockade of aldosterone action by means of MRAs has a cardioprotective effect. Several large randomized trials in heart failure patients unequivocally showed that adding small doses of MRA to the standard treatment regimen dramatically improves survival, which is partly attributable to a reduction of SCD events [21] [22] [23] .
In dialysis patients, the efficacy and safety of MRA have only been investigated by a few studies with small patient samples. Most of these studies focused on safety aspects of MRA, namely serum potassium levels. This issue has recently been reviewed [24, 25] and reassuringly no increase in the incidence of hyperkalaemia has been found in response to MRA treatment in dialysis patients. Thus, spironolactone appears to be safe in dialysis patients if close monitoring of electrolytes is performed, but additional large controlled trials are needed before definitive treatment recommendations can be made.
In contrast, efficacy of MRAs on CV end points in dialysis patients is not well characterized due to a paucity of clinical studies, small patient numbers and lack of appropriate methodology (Table 1) . Data from these studies suggest that systolic blood pressure is mildly reduced by MRA [26] [27] [28] and progression of carotid intima media thickness is blunted by MRA compared with placebo [27] . Moreover, in ESRD with concomitant moderate-to-severe systolic heart failure MRA improved LV ejection fraction [29, 30] . The effect on LV mass has been studied in two trials [30, 31] . McGill et al. treated 13 dialysis patients with 25 mg spironolactone for 270 days, but did not find any change in LV mass as assessed by cardiac magnet resonance (CMR) tomography. In contrast, Taheri et al. reported a significant reduction in LV mass as assessed by echocardiography following a 6-month treatment course with 25 mg spironolactone thrice weekly compared with placebo in 16 dialysis patients with moderate-to-severe heart failure. Thus, efficacy of MRAs in reducing LV mass in dialysis patients remains unclear given these contradictory results.
In conclusion, while treatment with a low-dose MRA appears to be safe in ESRD, evidence for CV efficacy remains sparse and cannot be advocated based on the existing data. We here report the design of the Mineralocorticoid Receptor antagonists in End-stage renal Disease (MiREnDa) trial, which systematically assesses CV efficacy and safety of 50 mg spironolactone once daily in dialysis patients.
M E T H O D S

Ethical considerations
The study protocol has been approved by the Ethics Review Committee of the University Hospital Wuerzburg, and the study will be performed according to the International Conference on Harmonisation-Good Clinical Practice guidelines and the Declaration of Helsinki. All study participants will provide written informed consent. A Data and Safety Monitoring Board will monitor safety throughout the study. The trial has been registered at clinical trials.gov (NCT01691053).
Patients
The study population consists of chronic haemodialysis patients. Inclusion and exclusion criteria are listed in Table 2 . We opted against the presence of LV hypertrophy as an inclusion criterion as the prevention of LV hypertrophy in patients with normal LV mass would be considered equally beneficial.
Study design and study visits
MiREnDa is a prospective randomized, placebo-controlled, double-blind, parallel group, multi-centre phase 2 intervention study investigating the efficacy and safety of spironolactone in haemodialysis patients. The study flow is depicted in Figure 1 . Patients will be screened and recruited at approximately 20 outpatient dialysis centres in Bavaria and Hesse, Germany. After providing informed consent, patients will be enrolled (screening visit) and enter a placebo run-in phase of 2-4 weeks. From this time point, regular study visits are scheduled before every dialysis session (i.e. three times per week) to monitor vital parameters, body weight, pre-dialysis potassium levels and adverse events until the end of the study. After establishment of compliance with the medication during the placebo run-in phase, patients will undergo a detailed CV assessment protocol (Week 0 visit) at one of the three university hospital centres (Wuerzburg, Frankfurt/Main, Erlangen/ Nuernberg). Subsequently, patients will be randomized 1:1 to the spironolactone or the placebo arm. Central computerized randomization will be stratified by intake of an ACEi and/or ARB (yes or no) and by the presence of LV hypertrophy (defined by an interventricular septum thickness of ≥12 mm, yes or no), using Pocock's minimization algorithm [32] . At the end of the double-blind treatment period, patients will undergo a repeat CV assessment protocol (Week 40 visit). Subsequently, study medication will be discontinued and patients will be monitored for another 4 weeks before the end of the study (end of study visit).
Objectives
MiREnDa will investigate CV effects and overall safety of spironolactone in dialysis patients. Predefined study end- Table 3 . The primary end point of the study is the change in the LV mass index (LVMI) as assessed by cardiac magnet resonance imaging (CMR). Secondary objectives comprise changes in cardiac geometry and function (CMR and echocardiography), blood pressure (office blood pressure, 24 h ambulatory blood pressure measurement), hospitalization or death due to heart failure, heart rate variability and cardiac arrhythmias (24 h ECG), exercise capacity (NYHA functional class, 6-min walk test), vascular function parameters (24 h pulse wave analysis, flow-mediated dilation of the brachial artery, aortic distensibility, carotid artery distensibility, carotid intima media thickness), quality of life (KDQOL-SF36) and anxiety/depression (HADS) and cardiac biomarkers of inflammation and fibrosis.
Hyperkalaemia management Potassium levels will be measured thrice weekly prior to each dialysis session. In the case of hyperkalaemia (defined as pre-dialysis potassium ≥6.0 mmol/L), possible causes will be explored and reacted upon according to local procedures (reduction of potassium levels in dialysis fluid, administration of potassium binders, etc.). In the case of a pre-dialysis potassium level of ≥6.0 but <6.5 mmol/L, study medication will be withheld until pre-dialysis potassium has dropped <5.5 mmol/ L prior to the next dialysis session. Study medication will then be restarted at half dose (25 mg daily). If pre-dialysis potassium remains stable <5.5 mmol/L for 2 weeks, study medication will be increased back to the full dose (50 mg daily).
In the case of a pre-dialysis potassium level ≥6.5 mmol/L, study medication will be stopped and study participation will be terminated. However, if continuation of study medication is considered safe by the nephrologist after discussion with the patient and the main study centre, study continuation may be considered in individual cases. Study medication will then be restarted as described above.
Sample size
The primary goal of the proposed study is to test the null hypothesis that the two population means (no treatment versus spironolactone) are equal with respect to change in LVMI over time as assessed by CMR. With a sample size of 33 in the control and 33 in the intervention arm, the study will have power of 80% to yield a statistically significant result (two-tailed alpha = 0.05). This computation assumes that the mean difference in LVMI between control and intervention groups is 7 g/m 2 with a common within-group standard deviation of 10 g/m 2 [15] . Such an effect can be considered moderately large and would be clinically important to detect, and can be anticipated in this field of research [12, 15] .
Due to the advanced chronic disease state and side effects of the study medication, a substantial drop-out rate is anticipated for the following reasons: (i) development of (painful) gynaecomastia resulting in early termination of the trial (10% of male patients on spironolactone: n = 3 patients [22, 33] ); (ii) development of hyperkalaemia (10% of the study sample: n = 12 patients [34] ); (iii) other reasons for premature termination of the trial including death or failure to complete repeat CMR (20% of the study sample: n = 24 [34, 35] ). Hence, an overall study size of n = 120 patients (60 per study arm) will allow for a drop-out of 39 subjects and thereby, preserve a power of 87%. Reduction in carotid intima media thickness progression by spironolactone; no effect on blood pressure (from 149 ± 26/ 83 ± 16 to 147 ± 19 / 78 ± 13 mmHg, P = n.s.)
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Statistical considerations
Intention-to-treat (ITT) analysis on the change of LVMI from baseline to Week 40 will be compared between groups using ANCOVA with the follow-up value as target variable, baseline value as covariate and group as factor. Secondary analyses will be done on the per-protocol population (i.e. 80% adherence of the study drug during a follow-up period of 40 ± 4 weeks).
Reference evaluations
Core laboratories will be established for analysis of CMR, echocardiography and CV data at the University Hospital Wuerzburg. All data will be analysed by readers blinded to treatment.
D I S C U S S I O N
Based on the favourable CV effects of MRA in the general population, there is a strong rationale for the use of these drugs in ESRD patients. CV mortality, in particular SCD, is extremely high in dialysis patients compared with the general population. This is partly explained by the high frequency of CV co-morbidities such as LV hypertrophy, congestive heart failure, high blood pressure and arterial stiffness. In the absence of severe kidney impairment, MRAs have proven highly efficacious in the treatment of these CV conditions. However, before embarking on a large clinical outcome trial efficacy and safety aspects of MRA have to be adequately addressed.
Safety
Can MRAs be considered safe in dialysis patients? A number of smaller clinical studies have provided reassuring data [24, 25] . In the largest study by Matsumoto et al., treatment of 61 haemodialysis patients with 25 mg spironolactone daily resulted in an average increase in pre-dialysis potassium of 0.3 mmol/L, which emerged after 2 weeks and stabilized subsequently [33] . Importantly, during the 8-month study period, no episodes of pre-dialysis potassium >6.5 mmol/L were observed. Gross et al. treated 8 dialysis patients with a spironolactone dose of 50 mg twice daily for a period of 2 weeks and reported an increase in pre-dialysis potassium from 4.7 to 5.0 mmol/L. In the absence of a functioning kidney, this increase is most likely explained by an increased retention of potassium, resulting from mineralocorticoid receptor blockade in the epithelium of the colon. In the MiREnDa study, we therefore expect a mild increase in predialysis potassium levels of ∼0.3 to 0.5 mmol/L, but no increase in the incidence of dangerous hyperkalaemia defined as a pre-dialysis potassium ≥6.5 mmol/L. In order to minimize hyperkalaemic events and optimize patient safety, dedicated exclusion criteria were defined, e.g. subjects who are likely to develop pre-dialysis potassium levels ≥6.0 mmol when taking the study medication (taking into account an expected increase of 0.3 to 0.5 mmol/L of pre-dialysis potassium) and patients with potassium levels ≥6.5 mmol/L within the last 3 months. In conclusion, MiREnDa will provide important information on safety aspects of spironolactone use in dialysis.
Efficacy
With regard to CV efficacy of MRAs in ESRD patients, there is a paucity of clinical studies (Table 1) . We chose the change in LV mass as measured by CMR as the primary end point in MiREnDa. First, the presence of LV hypertrophy is a common feature found in ∼75% of patients with ESRD when embarking on haemodialysis [6] . Second, LV mass is an independent predictor of prognosis [7] , and a reduction in LV mass has been shown to improve survival [9] . Third, LV mass can be measured accurately and reproducibly by CMR [12] . Fourth, there is good evidence that MRAs in the context of a functioning kidney are effective in reducing LV mass [12] [13] [14] [15] . In this respect, the study by Edwards et al. is of particular relevance because a reduction of LV mass by spironolactone has already been demonstrated in patients with underlying CKD, albeit at an earlier disease state. Notably, although only 10% of patients had overt LV hypertrophy by CMR measurement, MRA treatment was effective in reducing LV mass. However, it is important to stress that all these studies were conducted in the presence of a still functioning kidney and, thus, may not be directly transferable to the setting of haemodialysis. In contrast, efficacy of MRAs in dialysis patients to reduce LV mass remains unclear [30, 31] . The MiREnDa trial is expected to facilitate new pathomechanistic insights as it may prove a direct, kidney-independent effect of MRA on a CV target organ. Taken together, a change in LV mass appears to be an ideal end point to determine the CV efficacy of spironolactone in dialysis patients. A significant reduction in LV mass is likely to translate in a better outcome. Increased blood pressure is an independent risk factor for the development of LV hypertrophy and is a common clinical problem in ESRD patients [36] . In the presence of a functioning kidney, MRAs are potent antihypertensive agents, particularly in patients with treatment resistant essential hypertension [37, 38] . Data on blood pressure effects of MRA in ESRD patients are scarce but a reduction in systolic blood pressure has been reported [26, 28] . MiREnDa will carefully investigate blood pressure effects of spironolactone by means of regular office blood pressure measurements before and after each dialysis session and 24-h ambulatory blood pressure measurement before and at the end of the double-blind treatment period.
Systolic heart failure constitutes another common comorbidity in ESRD patients [39] . Although MRA have become an integral part of heart failure treatment in the general population, the prognostic benefit in ESRD patients remains to be shown. There is, however, accumulating evidence that blockade of the renin-angiotensin-aldosterone-system may be efficacious: Cice et al. [3] reported improved survival of dialysis patients with heart failure when telmisartan as opposed to placebo was added to background ACEi treatment; Taheri et al. [30] showed an improvement in LV ejection fraction in haemodialysis and continuous ambulatory peritoneal dialysis [29] patients with concomitant heart failure by addition of MRA. MiREnDa will shed further light on the effect of lowdose spironolactone on LV dimensions and function, NYHA class and exercise capacity in the subgroup of patients with underlying systolic heart failure.
In addition to cardiac parameters, MiREnDa will investigate MRA effects on vascular end points such as flowmediated dilatation of the brachial artery, carotid artery and aortic distensibility, carotid intima media thickness and 24-h ambulatory pulse wave analysis.
In summary, MiREnDa will provide insights into cardiac and vascular effects as well as safety of spironolactone in dialysis patients which will be of high relevance and importance in future studies.
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CO N F L I C T O F I N T E R E S T
None declared. F I G U R E 1 : Study flow chart. After enrolment of patients, patients will enter a 2-4 week placebo run-in phase to assess patient compliance with study medication. Patients will subsequently undergo CV baseline investigations (i.e. CMR imaging, echocardiography, vascular examination, 24 h ABPM, 24 h ECG, etc.) at one of the three university centers. Thereafter, patients will be randomized 1:1 to spironolactone (50 mg daily) or placebo. After 40 weeks of treatment, CV investigations will be repeated and study medication will be stopped. After a 4-week posttreatment surveillance phase, the study ends for the individual patient.
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